European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity

M. Lopez, P. Vici

Research output: Contribution to journalArticle

Abstract

The ability of dexrazoxane (DEX) to protect against anthracycline- induced cardiotoxicity has been evaluated in several European studies using either standard or high-dose regimens. In addition, one randomized trial investigated the value of cardiac radioimmunoscintigraphy with indium-III antimyosin monoclonal antibodies in the early detection of cardiac damage. The results of these trials demonstrate that DEX is able to ameliorate doxorubicin- and epirubicin-induced cardiotoxicity, even when high single drug doses are used. The cardioprotective effect of DEX has been clearly documented by both clinical and laboratory cardiac evaluation. The use of DEX did not add to the toxicity of the anthracyclines, nor was there clear evidence of an adverse impact of the agent on antitumor activity of the chemotherapeutic regimen. Radioimmunoscintigraphy was very sensitive in detecting anthracycline cardiac damage, but its specificity is low and it cannot be considered a primary test for guiding anthracycline treatment.

Original languageEnglish
Pages (from-to)55-60
Number of pages6
JournalSeminars in Oncology
Volume25
Issue number4 SUPPL. 10
Publication statusPublished - 1998

Fingerprint

Dexrazoxane
Epirubicin
Anthracyclines
Doxorubicin
Radioimmunodetection
Antineoplastic Agents
Monoclonal Antibodies
Cardiotoxicity
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology

Cite this

European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity. / Lopez, M.; Vici, P.

In: Seminars in Oncology, Vol. 25, No. 4 SUPPL. 10, 1998, p. 55-60.

Research output: Contribution to journalArticle

@article{972d307db0a64ec09509a1e93b62c963,
title = "European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity",
abstract = "The ability of dexrazoxane (DEX) to protect against anthracycline- induced cardiotoxicity has been evaluated in several European studies using either standard or high-dose regimens. In addition, one randomized trial investigated the value of cardiac radioimmunoscintigraphy with indium-III antimyosin monoclonal antibodies in the early detection of cardiac damage. The results of these trials demonstrate that DEX is able to ameliorate doxorubicin- and epirubicin-induced cardiotoxicity, even when high single drug doses are used. The cardioprotective effect of DEX has been clearly documented by both clinical and laboratory cardiac evaluation. The use of DEX did not add to the toxicity of the anthracyclines, nor was there clear evidence of an adverse impact of the agent on antitumor activity of the chemotherapeutic regimen. Radioimmunoscintigraphy was very sensitive in detecting anthracycline cardiac damage, but its specificity is low and it cannot be considered a primary test for guiding anthracycline treatment.",
author = "M. Lopez and P. Vici",
year = "1998",
language = "English",
volume = "25",
pages = "55--60",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "4 SUPPL. 10",

}

TY - JOUR

T1 - European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity

AU - Lopez, M.

AU - Vici, P.

PY - 1998

Y1 - 1998

N2 - The ability of dexrazoxane (DEX) to protect against anthracycline- induced cardiotoxicity has been evaluated in several European studies using either standard or high-dose regimens. In addition, one randomized trial investigated the value of cardiac radioimmunoscintigraphy with indium-III antimyosin monoclonal antibodies in the early detection of cardiac damage. The results of these trials demonstrate that DEX is able to ameliorate doxorubicin- and epirubicin-induced cardiotoxicity, even when high single drug doses are used. The cardioprotective effect of DEX has been clearly documented by both clinical and laboratory cardiac evaluation. The use of DEX did not add to the toxicity of the anthracyclines, nor was there clear evidence of an adverse impact of the agent on antitumor activity of the chemotherapeutic regimen. Radioimmunoscintigraphy was very sensitive in detecting anthracycline cardiac damage, but its specificity is low and it cannot be considered a primary test for guiding anthracycline treatment.

AB - The ability of dexrazoxane (DEX) to protect against anthracycline- induced cardiotoxicity has been evaluated in several European studies using either standard or high-dose regimens. In addition, one randomized trial investigated the value of cardiac radioimmunoscintigraphy with indium-III antimyosin monoclonal antibodies in the early detection of cardiac damage. The results of these trials demonstrate that DEX is able to ameliorate doxorubicin- and epirubicin-induced cardiotoxicity, even when high single drug doses are used. The cardioprotective effect of DEX has been clearly documented by both clinical and laboratory cardiac evaluation. The use of DEX did not add to the toxicity of the anthracyclines, nor was there clear evidence of an adverse impact of the agent on antitumor activity of the chemotherapeutic regimen. Radioimmunoscintigraphy was very sensitive in detecting anthracycline cardiac damage, but its specificity is low and it cannot be considered a primary test for guiding anthracycline treatment.

UR - http://www.scopus.com/inward/record.url?scp=0031658471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031658471&partnerID=8YFLogxK

M3 - Article

C2 - 9768825

AN - SCOPUS:0031658471

VL - 25

SP - 55

EP - 60

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 4 SUPPL. 10

ER -